CMS (HK) Successfully Completed the Listing of Mega Genomics Limited on HKEx
We are pleased to announce that on 22 June 2022, China Merchants Securities (HK) Co., Limited (“CMS (HK)”, a subsidiary of China Merchants Securities International Company Limited), acting as one of the Joint Global Coordinators, Joint Book Runners and Joint Lead Managers of Mega Genomics Limited (“Mega Genomics” or “the Company”, stock code: 6667.HK), successfully assisted the Company to commence trading of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEx”). A total of 11.96 million shares are issued and offered under the Global Offering, at an offer price of HK$18.00 per share, raising a total of approximately HK$215 million (before the exercise of the over-allotment option) or HK$248 million (assuming the over-allotment option is fully exercised).
Due to the current geopolitical conflicts and rising interest rates, the market volatility increases substantially. CMS (HK) does not fear difficulties and instead seize any opportunities to promote the investment highlights of the Company, and assisted the Company to be listed successfully on the HKEx. As one of the Joint Global Coordinators, CMS (HK) has accompanied Mega Genomics to overcome difficulties along the way and contributed to the successful listing with the trust and support from the Company.
Leveraging our extensive project experience and in-depth understanding of the healthcare sector, CMS (HK) assisted the Company to pinpoint its unique strengths as compared with its domestic and overseas competitors, and to fully showcase its investment highlights to investors whose confidence was further boosted through our continuous and timely communication. By fully utilizing our integrated platform and valuable client resources, CMS (HK) has selectively arranged top international and Chinese investors including long-only funds, private equity funds and multi-strategy funds to meet with the Company since last year and thus enabled them to obtain a better understanding of Mega Genomics’ brands, distribution channels and R&D capacity. After extensive investor outreach and marketing work, CMS (HK) was able to help Mega Genomics to attract quality investors, secure the cornerstone investment, and eventually complete the listing despite the current fluctuating market. The capital market has given positive response to Mega Genomics’ IPO, in which three cornerstone investors subscribed the shares in a total of approximately US$22.2 million. Both the International Placing and the Hong Kong Public Offering received slight over-subscription.
About Mega Genomics Ltd.
Mega Genomics is a leading genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. As of December 31, 2021, it performed over 12 million genetic tests since its establishment in 2016, with an average of over 246,000 tests performed per month in 2021. The Company is the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered. Also it was the largest genetic testing platform for cancer screening in China as measured by the number of tests administered in 2020.